Dossier assessment
Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.
Project details
- Project no.
- A23-15
- Commission
- Commission awarded on 01.03.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Finerenone (CKD stage 1 and 2) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15
Status: Commission completed
-
Dossier assessment
Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed